同仁堂科技(01666.HK)擬6.51億元向控股股東收購北京中藥加工基地資產
格隆匯11月4日丨同仁堂科技(01666.HK)發佈公告,於2019年11月4日,公司與集團公司(中國北京同仁堂(集團)有限責任公司,公司控股股東持有公司47.59%股權)訂立資產轉讓協議,集團公司已同意轉讓而公司已同意購買目標資產,將以現金人民幣6.51億元(含税)的方式支付。
目標資產位於北京市中關村科技園區大興生物醫藥基地,總建築面積88,753.01平方米,工業用地114,122.67平方米。目標資產由集團公司承擔土建施工建設,包括檢測中心、前處理廠房、成品分揀廠房等,主要功能為藥品檢驗、粉碎及淨料加工等中藥前處理生產以及物流配送等。
公司稱,目標資產以中藥前處理生產為主,集物流配送、藥品檢驗於一體,其與本公司大興分廠(以水蜜丸、大蜜丸等丸劑生產為主)相鄰,購買目標資產後,其將與本公司大興分廠形成協同效應,形成從中藥前處理、藥品生產再到物流配送為一體的閉環生產鏈,可有效降低公司營運成本;隨着公司大興分廠產能的逐步釋放,預期產量將隨之增長,目標資產將與現有前處理生產管理中心一起承擔公司所有中成藥產品的前處理工作,包括粉碎及淨料加工等工序,為本公司生產供應提供有力保障。
此外,目標資產的物流配送功能,將承擔着該公司及部分子公司產品的物流配送、調度工作,成品出廠後,統一進入該基地,再經銷售調度後發往全國各地。其物流配送功能設計儲存能力131萬件,設計吞吐能力6萬件/日,並採用先進的WMS倉儲管理系統、TMS車輛管理系統,充分滿足日常工作需求;及目標資產位於大興生物醫藥基地,區位優勢明顯,且隨着北京城南規劃落實及大興國際機場的投運,區位優勢更加顯現,未來該物業具有較明顯的增值潛力。本公司購買目標資產後,可直接獲得和享有未來物業增值的收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.